Cyclin E and survival in patients with breast cancer.
暂无分享,去创建一个
Isabelle Bedrosian | Thaddeus W Herliczek | Michael Lowe | Christopher Knickerbocker | G. Hortobagyi | T. Buchholz | I. Bedrosian | S. Tucker | K. Keyomarsi | S. Bacus | M. Lowe | T. Herliczek | W. Toyofuku | C. Knickerbocker | Gabriel N Hortobagyi | Thomas A Buchholz | Susan L Tucker | Khandan Keyomarsi | Matthew Callister | Ye Ding | Wendy Toyofuku | Sarah S Bacus | M. Callister | Ye Ding
[1] J. Peterse,et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J W Bacus,et al. Biological grading of breast cancer using antibodies to proliferating cells and other markers. , 1989, The American journal of pathology.
[3] I. Schieren,et al. Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kip1 expression. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[4] D. Conte,et al. Deregulation of cyclin E in breast cancer. , 1995, Oncogene.
[5] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[6] R. Bast,et al. Ploidy analysis of epithelial ovarian cancers using image cytometry. , 1992, Gynecologic oncology.
[7] I. Kleinschmidt,et al. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. , 2001, Human pathology.
[8] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[9] E. Lees,et al. Cyclin E, a potential prognostic marker for breast cancer. , 1994, Cancer research.
[10] W. S. Lazarus-Barlow,et al. THE NATURAL DURATION OF CANCER , 1924, British medical journal.
[11] M. Gossen,et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.
[12] Ruby Sg,et al. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma. , 1993 .
[13] J. Decaprio,et al. Cyclin E, a redundant cyclin in breast cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] James M. Roberts,et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition , 1995, Molecular and cellular biology.
[15] K. Palucka,et al. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. , 1996, Blood.
[16] G. Landberg,et al. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. , 1996, British Journal of Cancer.
[17] K. Keyomarsi,et al. The role of cyclin E in cell proliferation, development and cancer. , 1997, Progress in cell cycle research.
[18] L. Titus-Ernstoff,et al. Central values and variation of measured nuclear DNA content in imprints of normal tissues determined by image analysis. , 1989, Cytometry.
[19] J. A. Hamilton,et al. Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.
[20] A. Pardee,et al. Cyclin E and cyclin A as candidates for the restriction point protein. , 1993, Cancer research.
[21] S. Reed,et al. Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast , 1991, Cell.
[22] Q. Dou,et al. Cyclin E — a better prognostic marker for breast cancer than cyclin D? , 1996, Nature Medicine.
[23] L. Kèlland,et al. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. , 1994, British Journal of Cancer.
[24] J. Bacus,et al. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. , 1988, American journal of clinical pathology.
[25] D. Cox. Regression Models and Life-Tables , 1972 .
[26] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[27] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[28] D. Bortner,et al. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.
[29] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[30] S. Reed,et al. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. , 1992, Genes & development.
[31] Mollianne J. McGahren,et al. Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms , 2001, Molecular and Cellular Biology.
[32] K. Keyomarsi,et al. Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[33] K. Keyomarsi,et al. Processing of cyclin E differs between normal and tumor breast cells. , 2000, Cancer research.